#USA #Los Angeles #phage therapy #Armata Pharmaceuticals #AP-PA02

Armata Pharmaceuticals Releases Q4 and Full-Year 2024 Results

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has recently shared its financial results for the fourth quarter and entire year ending December 31, 2024. The clinical-stage biotech firm is dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics aimed at combating antibiotic-resistant bacterial infections.

Key Developments in Q4 2024

During this quarter, the company achieved meaningful clinical milestones, especially with the Phase 2 Tailwind study of its inhaled drug candidate, AP-PA02, designed to treat Pseudomonas aeruginosa (P.a.) infections in patients suffering from non-cystic fibrosis bronchiectasis (NCFB). Noteworthy findings include:

• - The study showcased that AP-PA02 is well-tolerated by patients, with adverse events being mild and temporary.
• - A post-hoc analysis indicated a statistically significant decrease in P.a. colony-forming units (CFUs) in treated patients within one to two weeks post-treatment. One-third of subjects displayed at least a 2-log reduction in CFUs, showcasing the potential of phage therapy as an effective alternative to traditional antibiotics.

This particular trial marks a second successful clinical investigation for AP-PA02, following the Phase 1b/2a SWARM-P.a. study conducted in 2023, which evaluated the therapy in cystic fibrosis patients. The recent results provide a solid foundation for both the ongoing and future clinical paths for Armata’s innovative treatment approaches.

In parallel, Armata completed enrollment for the Phase 1b/2a diSArm study focusing on another candidate, AP-SA02, targeting Staphylococcus aureus bacteremia. The blinded data from this trial indicates that intravenous AP-SA02, administered in high doses, is safe and well-tolerated among patients. The anticipated topline results are expected early in 2025.

Company’s Financial Overview

Armata's financial results for Q4 2024 reveal a grant revenue of $1.2 million, down from $1.5 million in Q4 of 2023. The research and development expenses totaled approximately $8.5 million, showing a slight rise from $7.9 million in the same quarter the previous year, reflecting continued investment into primary development programs.

The company recorded a loss from operations of approximately $10.5 million for Q4 2024, a slight increase compared to a $9.6 million loss in Q4 2023. Yet, there was a notable net income of $2.6 million for the quarter, improved from a net loss of $19.8 million in the same period last year. This change is attributed to non-cash gains from the fair value changes of convertible loans.

As of December 31, 2024, Armata reported $14.8 million in cash and equivalents, along with a new secured credit agreement of $10 million with Innoviva Strategic Opportunities LLC. This agreement is expected to bolster the company’s financial stability as they continue navigating the complexities of drug development and clinical trials.

Future Directions

Dr. Deborah Birx, CEO of Armata, expressed optimism regarding the progress made in the clinical trials and the introduction of phage therapy as a viable alternative to traditional antibiotics. The company is committed to addressing the pressing global health crisis caused by antimicrobial resistance and is eager to finalize a pivotal trial strategy with the FDA to validate their methods further.

Armata is proactively developing a broad pipeline of natural and synthetic phage candidates, illustrating its commitment to pioneering phage therapy advancements. With the promising results from its current studies and strategic partnerships, Armata strives to reshape the landscape of antibiotic treatment in a meaningful way.

In conclusion, Armata Pharmaceuticals stands at a crucial juncture in its development trajectory, driven by innovation, promising clinical results, and a strategic commitment to tackling some of the most challenging health issues of our time. Investors and observers alike will be keenly watching as the company moves forward into the pivotal phases of its clinical research and development agendas.